Comparing high‐dose cisplatin with cisplatin‐based combination chemotherapy in definitive concurrent chemoradiation setting for locally advanced head and neck squamous cell carcinoma (LAHNSCC)

Muhammad Furqan; Travis P Snyders; Mohammed U Saqlain; Sarah L Mott; Douglas Laux; Anthony Snow; Carryn M Anderson; John M Watkins; Gerald H Clamon

doi:10.1002/cam4.2139

Back

Comparing high‐dose cisplatin with cisplatin‐based combination chemotherapy in definitive concurrent chemoradiation setting for locally advanced head and neck squamous cell carcinoma (LAHNSCC)

Journal article

Open access

Peer reviewed

Comparing high‐dose cisplatin with cisplatin‐based combination chemotherapy in definitive concurrent chemoradiation setting for locally advanced head and neck squamous cell carcinoma (LAHNSCC)

Muhammad Furqan, Travis P Snyders, Mohammed U Saqlain, Sarah L Mott, Douglas Laux, Anthony Snow, Carryn M Anderson, John M Watkins and Gerald H Clamon

Cancer medicine (Malden, MA), Vol.8(6), pp.2730-2739

06/2019

DOI: 10.1002/cam4.2139

PMCID: PMC6558467

PMID: 30968604

Files and links (1)

url

https://doi.org/10.1002/cam4.2139View

Published (Version of record) Open Access

Abstract

Background High‐dose cisplatin (Cis) is a preferred systemic agent for concurrent chemoradiation (CRT) in locally advanced head and neck squamous cell cancer (LAHNSCC) patients. As some patients are unable to tolerate Cis, this study compares the toxicity and efficacy of weekly cisplatin‐paclitaxel (CP) regimen with Cis. Methods Patients with LAHNSCC receiving definitive chemoradiation either with Cis (Cisplatin—100 mg/m2 q3w x 3) or CP (Cisplatin—20 mg/m2; Paclitaxel—30 mg/m2qw x7) were included. Results Cis and CP groups were comprised of 114 and 111 subjects, respectively. Complete response for Cis versus CP groups was 88% versus 88%, respectively. Median follow‐up for the study was 58.5 months. After adjusting for potential treatment selection bias, no significant differences were evident between Cis and CP groups for overall survival (hazard ratios [HR] 0.85, 95% CI 0.59‐1.21, P = 0.36), progression free survival (HR 0.88, 95% CI 0.62‐1.24, P = 0.46), locoregional control (HR 0.77, 95% CI 0.52‐1.15, P = 0.21), and distant control (HR 0.87, 95% CI 0.61‐1.23, P = 0.42). Patients in the CP group had less acute and chronic toxicities. Conclusions Weekly CP regimen can serve as an alternative systemic therapy with radiation in patients with LAHNSCC who are not fit for Cis. Concurrent chemoradiation with weekly cisplatin and paclitaxel is tolerable and provide higher compliance rate in patients with locally advanced head and neck squamous cell carcinoma. Outcomes of patients on combination chemotherapy were similar to high‐dose cisplatin.

Head and neck cancer

chemotherapy

radiation therapy

Details

Title: Subtitle: Comparing high‐dose cisplatin with cisplatin‐based combination chemotherapy in definitive concurrent chemoradiation setting for locally advanced head and neck squamous cell carcinoma (LAHNSCC)
Creators: Muhammad Furqan - University of Iowa Hospitals and Clinics
Travis P Snyders - University of Iowa Hospitals and Clinics
Mohammed U Saqlain - University of Iowa Hospitals and Clinics
Sarah L Mott - University of Iowa Hospitals and Clinics
Douglas Laux - University of Iowa Hospitals and Clinics
Anthony Snow - University of Iowa Hospitals and Clinics
Carryn M Anderson - University of Iowa Hospitals and Clinics
John M Watkins - University of Iowa Hospitals and Clinics
Gerald H Clamon - University of Iowa Hospitals and Clinics
Resource Type: Journal article
Publication Details: Cancer medicine (Malden, MA), Vol.8(6), pp.2730-2739
DOI: 10.1002/cam4.2139
PMID: 30968604
PMCID: PMC6558467
NLM abbreviation: Cancer Med
ISSN: 2045-7634
eISSN: 2045-7634
Number of pages: 10
Grant note: The Holden Comprehensive Cancer Center Gift Funds The Holden Comprehensive Cancer Center at The University of Iowa and its National Cancer Institute (P30CA086862)
Language: English
Date published: 06/2019
Academic Unit: Hematology, Oncology, and Blood & Marrow Transplantation; Pathology; Radiation Oncology; Internal Medicine
Record Identifier: 9984047669002771

Metrics

33 Record Views

8 Times Cited - Web of Science